Please login to the form below

Not currently logged in


This page shows the latest Nexletol news and features for those working in and with pharma, biotech and healthcare.

Esperion gets FDA thumbs up for cholesterol drug Nexletol

Esperion gets FDA thumbs up for cholesterol drug Nexletol

Big comeback after previous trial fail. US biopharma Esperion has secured US Food and Drug Administration (FDA) approval for its cholesterol-lowering drug Nexletol in a big comeback after a safety ... Nexletol won’t be able to make a similar claim

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Reaching patients and HCPs during the pandemic Reaching patients and HCPs during the pandemic

    Esperion planned to launch its lipid-lowering agent, Nexletol (bempedoic acid), in March 2020 before releasing the combination therapy, Nexlizet (bempedoic acid/ezetimibe), in July. ... When the pandemic hit, Esperion decided to push ahead with the March

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Research Partnership

Research Partnership is now a member of Inizio Advisory, the consulting business unit of Inizio, a strategic partner for health...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....